Our meta-analysis suggests that CAR-T cell therapy could address the negative effects associated with high-risk cytogenetics (≤50% vs. > 50% = 84.21% vs. 82.17%) and exhibited a higher efficacy against MM resistant to previous therapies including IMiDs, PIs, anti-CD38 monoclonal antibody, and ASCT. The gene discussed is CD38; the disease is Miyoshi myopathy.